Icatibant Acetate

CAS 138614-30-9
Back to the Catalog Contact us about this API

General Information

Icatibant acetate is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults. HAE is a rare, potentially life-threatening disease characterized by intermittent and unpredictable attacks of sudden swelling involving various organs.

About the API

Molecular Formula C61H93N19O15S
Molecular Weight 1364.59
Therapeutic category Blood and Blood Forming Organs
Available formulations Injectables
Regulations Canada DMF Flag Canada DMF US DMF Flag US DMF

Updates about Icatibant Acetate

  • Jun 27, 2016 New US DMF for Icatibant Acetate dated 6/2016 is available.
  • Feb 02, 2020 New Canada DMF for Icatibant Acetate is available.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.

This site uses cookies (unless you have disabled them) to give you a better and personalized browsing experience and targeted ads.
By continuing your visit on this website, you agree to the use of Cookies on your device. Find out more in our Privacy Policy